Prospects for the Use of Indole-3-carbinol in the Treatment of Benign Prostatic Hyperplasia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to establish the possibility of the effect of indole-3-carbinol on the inflammatory component in men with benign prostatic hyperplasia by assessing symptoms before and after treatment.
Materials and methods. The Institute of Sexology and Andrology LLC observed 142 male patients with BPH I degree, which were divided into three clinical groups. Group I included patients (n=39) who received a combination of I3C extract (Invitol) and Тamsulosin 0,4 mg/day; the second – patients (n=71) who received standard therapy, with the inclusion of Тamsulosin 0,4 mg/day; in III – (n=32) persons who did not receive treatment at all. The control group consisted of 30 healthy men. Invitol was prescribed in a dose of 1 capsule twice a day. After eating for 12 weeks, Тamsulosin at a dose of 0,4 mg/day once in the morning after eating for 12 weeks. The age of patients ranged from 50,2 to 62,5 years, on average – 56,2±3,2 years. The duration of the disease is from 3,5 to 7 years (on average 5,5±0,8 years). Before and during the treatment, all patients underwent traditional examinations.
Results. Based on the results of examinations in patients with BPH who received conservative therapy, it follows that: the concomitant inflammatory process in the tissues of the prostate gland requires the use of pathogenetic agents, which include natural catechin – indole-3-carbinol in combination with selective α-blocker; the combination of Invitol Invitol and tamsulosin prescribed to patients contributed to a significant decrease in leukocyturia levels by 5,1 times and bacteriuria by 7,1 times (p<0,001) than traditional tamsulosin monotherapy.
Conclusion. The combination of Invitol and tamsulosin creates the conditions for a faster recovery of IPSS and QoL in people with BPH than traditional tamsulisin monotherapy.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Аляев Ю.Г., Аполихин О.И., Мазо Е.Б. и соавт. (2010) Результаты трехлетнего клинического исследования по изучению эффективности и безопасности препарата Простамол® Уно у больных с начальными проявлениями аденомы предстательной железы и риском прогрессирования // Урология. – № 6. – С. 3–10.
Мазо Е.Б., Дмитриев Д.Г., Зиканов В.В. (2005) Комбинированное лечение больных доброкачественной гиперплазией предстательной железы в сочетании с хроническим простатитом при подозрении на рак предстательной железы // РМЖ. – № 13 (9). – С. 615–618.
Горпинченко И.И., Гурженко Ю.Н., Спиридоненко В.В. (2014) Сучасні дані про вплив хронічного запалення в патогенезі доброякісної гіперплазії і раку передміхурової залози // Здоровье мужчины. – № 4 (51). – С. 91–95.
Горпинченко И.И., Гурженко Ю.Н., Спиридоненко В.В. (2015) Исследование эффективности использования комплексной терапии доброкачественной гиперплазии предстательной железы с применением препаратов Тамсулозин, Простаплант-форте, Простаплант // Здоровье мужчины. – № 3 (54). – С. 10–16.
Nickel J.C. Prostatic inflammation in BPH: the third component? (1994) //Can J Urol. – V. 1 – P. 1–4.
De Marzo A.M., Platz E.A., Sutcliffe S. et al. (2007) Inflammation in prostate carcinogenesis // Nat Rev. – V. 7. – P. 256–269.
De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G. (1999) Proliferative inflammatory atrophy of the prostate // Am. J.Pathol. – V. 155. – P. 1985–1992.
Nelson W.G., De Marzo A.M., IsaacsW.B. (2003) Prostate cancer // N. Engl. J. Med. – V. 349. – P. 366–381.
Platz E.A., De MarzoA.M. (2004) Epidemiology of inflammation and prostate cancer // J Urol. – V. 171. – P. 536–540.
Kramer G., Mitteregger D., Marberger M. (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? // Eur Urol. – V. 51. – P. 1202–1216.
Di Silverio F, Gentile V., De Matteis A. et al. (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis // Eur Urol. – V. 43. – P. 164–175.
Djavan B. (2003) Lower urinary tract symptoms benign prostatic hyperplasia: fast control of the patient’s quality of life // Urology. Sep;62(3 Suppl 1): P. 6–14.
Dennis L., Lynch C.F., Tornes J.C. (2002) Epidemiologic association between prostatitis and prostate cancer // Urology. – V. 60. – P. 78–83.
Karakiewicz P.I., Benayoun S., Begin L.R. et al. (2007) Chronic inflammation is negatively associated with prostate cancer and high grade prostatic intraepithelial neoplasia on needle biopsy // Int J Clin Pract. – V. 71. – P. 425–430.
Romaniuk M., Gorpynchenko I., Gurzhenko J., Klimenko P., Shulyak A., Spyrydonenko V. (2013) S42 PROSPECT study (PROStamol: PErspectives of Combined Therapy) in patients with BPH // Eur. Urol. Suppl. October – V. 12, I. 4, P.e1150, S42ю.
Manson MM, Farmer PB, Gescher A, Steward WP. (2005) Innovative agents in cancer prevention. Recent Results Cancer Res.;166:257-75.
Atawodi SE. (2011) Nigerian foodstuffs with prostate cancer chemopreventive polyphenols. Infect Agent Cancer. Sep 23;6 Suppl 2:S9.
Kim EK, Kim YS, Milner JA, Wang TT. (2013) Indole-3-carbinol and 3’,3’–diindolylmethane modulate androgen’s effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells. Cancer Prev Res (Phila). Jun;6(6):519-29.
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. (2015) Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. Dec;35 Suppl:S25-S54.
Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E. (2012) 3,3’-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol. Sep 15;263(3):345-51.
Brandt JZ, Silveira LT, Grassi TF, Anselmo-Franci JA, Fávaro WJ, Felisbino SL, Barbisan LF, Scarano WR. (2014) Indole-3-carbinol attenuates the deleterious gestational effects of bisphenol A exposure on the prostate gland of male F1 rats. Reprod Toxicol. Jan;43:56-66.
Sarkar FH, Li Y. (2004) Indole 3-carbinol and prostate cancer. J Nutr. Dec;134 (12 Suppl):3493S-3498S.
Wang TT, Schoene NW, Milner JA, Kim YS. (2012) Broccoli-derived phytochemicals indole-3-carbinol and 3,3’-diindolylmethane exerts concentrationdependent pleiotropic effects on prostate cancer cells: comparison with other cancer preventive phytochemicals. Mol Carcinog. 2012 Mar;51(3):244-56.
Nachshon-Kedmi M, Yannai S, Haj A, Fares FA. (2003) Indole-3-carbinol and 3,3’-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol. Jun;41(6):745-52.
Li Y, Li X, Sarkar FH. (2003) Gene expression profiles of I3C– and DIMtreated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr. Apr;133(4):1011-9.
Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS. (2007) A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res. Aug 15;67(16):7815-24.
Howells LM, Hudson EA, Manson MM. (2005) Inhibition of phosphatidylinositol 3-kinase/protein kinase B signaling is not sufficient to account for indole-3-carbinol-induced apoptosis in some breast and prostate tumor cells. Clin Cancer Res. Dec 1;11(23):8521-7.
Watson G, Beaver L, Williams D, Dashwood R, Ho E. (2013) Phytochemicals from cruciferous vegetables, epigenetics, and prostate cancer prevention. AAPS J. 2013 Oct;15(4):951-61.
Bradlow HL. (2008) Review. Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer. In Vivo. Jul-Aug;22(4):441-5.
Nwankwo JO. (2002) Anti-metastatic activities of all-trans retinoic acid, indole-3-carbinol and (+)-catechin in Dunning rat invasive prostate adenocarcinoma cells. Anticancer Res. 2002 Nov-Dec;22(6C):4129-35.
Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, Sarkar FH. (2010) A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3’-Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res. Jul 23;2(4):402-11.
Kul’chavenia EV, Breusov AA, Brizhatiuk EV, Kholtobin DP. (2010) Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections. Urologiia. Nov-Dec;(6):55-8.
Licznerska B, Baer-Dubowska W. (2016) Indole-3-Carbinol and Its Role in Chronic Diseases. Adv Exp Med Biol.;928:131-154.
Adwas AA, Elkhoely AA, Kabel AM, Abdel-Rahman MN, Eissa AA. (2016) Anti-cancer and cardioprotective effects of indol-3-carbinol in doxorubicintreated mice. J Infect Chemother. Jan;22(1):36-43.
Wang SQ, Cheng LS, Liu Y, Wang JY, Jiang W. (2016) Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection. Curr Drug Metab.;17(4):401-9.
Martín-Ruiz A, Peña L, González-Gil A, Díez-Córdova LT, Cáceres S, Illera JC. (2018) Effects of indole-3-carbinol on steroid hormone profile and tumor progression in a mice model of canine inflammatory mammarycancer. BMC Cancer. Jun 4;18(1):626.
Megna BW, Carney PR, Nukaya M, Geiger P, Kennedy GD. (2016) Indole-3-carbinol induces tumor cell death: function follows form. J Surg Res. Jul;204(1):47-54.
El-Naga RN, Mahran YF. (2016) Indole-3-carbinol protects against cisplatin-induced acute nephrotoxicity: role of calcitonin gene-related peptide and insulin-like growth factor-1. Sci Rep. Jul 15;6:29857.
Ampofo E, Schmitt BM, Menger MD, Laschke MW. (2018) Targeting the Microcirculation by Indole-3-carbinol and Its Main Derivate 3,3,’-diindolylmethane: Effects on Angiogenesis, Thrombosis and Inflammation. Mini Rev Med Chem.;18(11):962-968.
Lane JA, Er V, Avery KNL, Horwood J, Cantwell M, Caro GP, Crozier A, Smith GD, Donovan JL, Down L, Hamdy FC, Gillatt D, Holly J, Macefield R, Moody H, Neal DE, Walsh E, Martin RM, Metcalfe C. (2018) ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prev Res (Phila). Nov;11(11):687-696.
Ilic D, Forbes KM, Hassed C. (2011) Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. Nov 9;(11).
Beynon RA, Richmond RC, Santos Ferreira DL, Ness AR, May M, Smith GD, Vincent EE, Adams C, Ala-Korpela M, Würtz P, Soidinsalo S, Metcalfe C, Donovan JL, Laneс AJ, Martin RM. (2019) ProtecT Study Group; PRACTICAL consortium. Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial. Int J Cancer. Apr 15;144(8):1918-1928.
van Die MD, Bone KM, Emery J, Williams SG, Pirotta MV, Paller J. (2016) Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials. BJU Int. 2016 Apr;117 Suppl 4:17-34.
Horwood JP, Avery KN, Metcalfe C, Donovan JL, Hamdy FC, Neal DE, Lane JA. (2014) Men’s knowledge and attitudes towards dietary prevention of a prostate cancerdiagnosis: a qualitative study. BMC Cancer. Nov 5;14:812.
Lin C, Shin DG, Park SG, Chu SB, Gwon LW, Lee JG, Yon JM, Baek IJ, Nam SY. (2015) Curcumin dosedependently improves spermatogenic disorders induced by scrotal heat stress in mice. Food Funct. Dec;6(12):3770-7.
Bahadir Koca S, Ongun O, Ozmen O, Yigit NO. (2019) Subfertility effects of turmeric (Curcuma longa) on reproductive performance of Pseudotropheus acei. Anim Reprod Sci. Mar;202:35-41.
Eun CS, Lim JS, Lee J, Lee SP, Yang SA. (2017) The protective effect of fermented Curcuma longa L. on memory dysfunction in oxidative stress-induced C6 gliomal cells, proinflammatoryactivated BV2 microglial cells, and scopolamine-induced amnesia model in mice. BMC Complement Altern Med. Jul 17;17(1):367.
Zhang L, Diao RY, Duan YG, Yi TH, Cai ZM. (2017) In vitro antioxidant effect of curcumin on human sperm quality in leucocytospermia. Andrologia. Dec;49(10).
Ashok R, Ganesh A, Deivanayagam K. (2017) Bactericidal Effect of Different Anti-Microbial Agents on Fusobacterium Nucleatum Biofilm. Cureus. Jun 11;9(6):e1335.
Akinyemi AJ, Adedara IA, Thome GR, Morsch VM, Rovani MT, Mujica LKS, Duarte T, Duarte M, Oboh G, Schetinger MRC. (2015) Dietary supplementation of ginger and turmeric improves reproductive function in hypertensive male rats. Toxicol Rep. Oct 13;2:1357-1366.
